Celltrion Archives | Be Korea-savvy
Celltrion’s Autoimmune Disease Biosimilar to Land in U.S. in July 2023

Celltrion’s Autoimmune Disease Biosimilar to Land in U.S. in July 2023

SEOUL, April 27 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday it will begin sales of its autoimmune disease biosimilar Yuflymain in the United States in July 2023. The plan comes as Celltrion has settled a patent dispute with U.S. drugmaker AbbVie Inc. Yuflyma — a biosimilar referencing blockbuster drug Humira — [...]

Celltrion’s Autoimmune Disease Biosimilar Lands in S. Korea

Celltrion’s Autoimmune Disease Biosimilar Lands in S. Korea

SEOUL, March 2 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its autoimmune disease biosimilar Yuflyma has begun sales in the domestic market. Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie Inc. — is used to treat patients with multiple chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. [...]

Celltrion Expects COVID-19 Treatment Candidate to Show Efficacy Against Omicron

Celltrion Expects COVID-19 Treatment Candidate to Show Efficacy Against Omicron

SEOUL, Feb. 24 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. on Thursday anticipated its antibody treatment against COVID-19 under development would show efficacy against the omicron variant. Celltrion said that CT-P63 has maintained strong neutralizing ability against the omicron variant during pseudo-virus testing. The candidate treatment is currently under clinical trials. The announcement [...]

Celltrion’s Autoimmune Disease Biosimilar Wins Further Approval in Europe

Celltrion’s Autoimmune Disease Biosimilar Wins Further Approval in Europe

SEOUL, Feb. 22 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Tuesday that a high-concentration version of its autoimmune disease biosimilar Yuflyma has won approval from European drug authorities. The European Medicines Agency (EMA) gave the green light to Celltrion’s application to sell Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie [...]

Celltrion 2021 Net Soars 20 pct on Robust Overseas Sales

Celltrion 2021 Net Soars 20 pct on Robust Overseas Sales

SEOUL, Feb. 16 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday that its net profit jumped 20.1 percent on-year last year on the back of robust sales of its biosimilar products in overseas markets. Net profit came to 623.7 billion won (US$521.1 million) last year on a consolidated basis, compared [...]

Celltrion’s Inhaled COVID-19 Treatment Found to be Safe in Clinical Trial

Celltrion’s Inhaled COVID-19 Treatment Found to be Safe in Clinical Trial

SEOUL, Feb. 7 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its inhaled version of an antibody treatment candidate against COVID-19 has shown to be safe in a clinical trial. A total of 24 healthy volunteers were enrolled in a phase one clinical trial conducted by Celltrion’s global partner, Inhalon Biopharma, [...]

Celltrion’s COVID-19 Antibody Treatment Wins Temporary Approval in Switzerland

Celltrion’s COVID-19 Antibody Treatment Wins Temporary Approval in Switzerland

SEOUL, Jan. 14 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Friday its COVID-19 antibody treatment has won temporary approval from Swedish authorities. Swissmedic granted Temporary Authorization of Rekirona for adult COVID-19 patients who do not require supplementary oxygen treatment and are at high risk of developing into severe cases. The approval will [...]

Celltrion’s COVID-19 Self-test Kit Available on Amazon

Celltrion’s COVID-19 Self-test Kit Available on Amazon

SEOUL, Jan. 6 (Korea Bizwire) — South Korean biopharmaceutical company Celltrion Inc. said Thursday that its self-diagnostic kit for COVID-19 is available for purchase on global retailer Amazon. Celltrion DiaTrust COVID-19 Ag Home Test, co-developed by local health care business Humasis, received the U.S. Food and Drug Administration’s Emergency Use Authorization approval last year. The [...]

Celltrion’s COVID-19 Candidate Treatment Shows Safety in Clinical Trial

Celltrion’s COVID-19 Candidate Treatment Shows Safety in Clinical Trial

SEOUL, Jan. 3 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its antibody treatment candidate against COVID-19 has shown safety in its clinical trial. Celltrion said it has enrolled 24 healthy volunteers in its global phase one clinical trial and confirmed the safety, tolerability and pharmacokinetics of CT-P63. Separately, Celltrion said [...]